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Abstract 
Despite high levels of psychological distress, there is a scarcity of research on unmet supportve care 
needs in haematological cancer patents.  This qualitatve study used an in-depth interpretatve 
phenomenological approach to investgate the needs reported by six Non-Hodgkin lymphoma patents 
and explored how these needs consequently shaped the patent experience.  Emergent themes 
included: concerns for family, informaton needs and the need for psychological support.  Partcipants 
reported feeling diferent to other cancer patents.  Lack of understanding of their diagnosis by friends 
and family, and access to relevant support services, are notable unmet needs that difer from previous 
findings.
Introduction
Being diagnosed with a life threatening illness such as cancer can induce significant levels of emotonal 
and psychological distress for both patents and their loved ones (Holland and Alici, 2010; Pitceathly and 
Maguire, 2003).  Haematological cancers are a unique and highly diverse groups of diseases that are 
known to impact upon a person’s wellbeing (Molassiots et al, 2011; Manita et al, 2011; Montgomery et
al., 2003), with key diferences between these diseases and solid cancerous tumours. Yet, there is a lack 
of published research relatng to the specific unmet supportve care needs that are most pertnent for 
this patent group (Swash, Hulbert-Williams and Bramwell, 2014).
Haematological cancers display several key diferences to solid tumours such as breast, lung or 
colorectal cancer.   There are pathological diferences that can afect treatment type, but, perhaps more 
importantly for patents, which translate into diferences in the organisaton of services; there is a clear 
degree of separaton from those services aimed at solid tumours (NICE, 2003).  There are also access 
diferences: people with haematological cancers are more likely to be treated in local district general 
hospitals rather than specialist cancer units, they are less likely to receive specialist palliatve care, and 
they are more likely to die in hospital (Howell et al, 2011).  The reasons behind this are complex and not 
well defined.  Treatment for haematological cancers can either be notably intensive, impactng upon 
social, vocatonal and functonal roles (Sherman et al, 2005) or, conversely, patents may not be treated 
at all and instead monitored via a ‘watch and wait’ regime, creatng a mismatch with the common 
understanding of what will happen when you receive a cancer diagnosis (Evans, Ziebland and Pett, 
2012).  In either case, receiving a diagnosis of this kind can have a significant impact upon a person’s 
psychological wellbeing and the way in which they contnue their everyday lives.  
As haematological cancers difer from solid tumours in such basic ways, it is difcult to predict the 
extent to which the most common and disabling psychosocial concerns to afect this patent group may 
align with those identfied by patents with other cancer diagnoses.  Psychosocial needs are theoretcally
well defined and this framework has been repeatedly applied within cancer populatons (Sanson-Fisher 
et al, 2000; Morrison et al, 2012; Armes et al, 2009).  Commonly identfied unmet needs in general 
cancer groups include: informaton needs, needs relatng to healthcare professionals, and practcal 
needs (Harrison et al, 2009).  What is less well understood is whether the needs of haematology patents
coincide with those of other cancer patents, and to what degree the diferences in presentaton and 
care result in diferent unmet psychosocial needs, and indeed whether the impact of these needs can 
provide an explanaton for diferent profiles of psychological wellbeing.  
There is a paucity of research that explores the experiences of people diagnosed with lymphoma 
(Elphee, 2008; Caldwell, 2014).  A thorough understanding of patent experiences and unmet needs is 
vital if we are to adequately and efectvely implement psychological or supportve care interventons for
diferent patent groups. The lack of knowledge of specific needs in haematological cancer are thus a 
considerable barrier to high quality care.  This study aims to investgate: (i) the experiences of 
psychosocial needs in haematological cancer patents, (ii) why specific needs were felt to be important, 
and (iii) the impact that unmet needs had on the overall patent experience.
Methodology
Procedure
Three small focus groups were conducted with patents with Non-Hodgkin’s lymphoma, the most 
common type of haematological cancer diagnosed in the UK (Cancer Research UK, 2014).  The focus 
groups were designed to explore the type of needs that patent’s had throughout their experiences of 
diagnosis, treatment and survivorship.
All three focus groups were conducted within a hospital setng in the North West of England, although 
away from the ward environment for privacy and comfort.  Focus groups were audio recorded and 
subsequently transcribed verbatm.   The transcripts were analysed using Interpretatve 
Phenomenological Analysis (IPA: Smith, 2004; Smith and Osbourn, 2004; Palmer et al, 2010).  The lead 
researcher completed inital analysis of all transcripts, with all transcripts independently verified by a 
second researcher.  Once a first draf of the results narratve was complete, the second researcher again
reviewed the transcripts to provide a second level of validaton to ensure that the analysis framework 
proposed fited with the raw data accurately.  In this way, the validaton of themes became part of the 
analysis process as it added a further layer to the exploraton and interpretaton of the data.    
All focus groups were conducted by the lead researcher, with the assistance of a co-facilitator to help 
with practcalites.  The average length of tme for the focus groups was 90 minutes.  
Ethical approval for the study was obtained from NREC and the University of Chester Department of 
Psychology Ethics Commitee, and local research governance was obtained at the partcipatng NHS 
trust.
Sample
Partcipants with a diagnosis of a haematological cancer were recruited via Consultant Haematologists in
outpatent clinics in a hospital in the North West of England.  Informaton packs were provided to 
partcipants by their Consultant Haematologist during routne clinic appointments, with an opton to 
speak with the researcher if desired.  Partcipants were required to be at least 18 months post-diagnosis 
and to have completed their treatment regimes.  Any haematological cancer diagnosis was initally 
deemed acceptable for the study; however, all consentng partcipants had a diagnosis of Non-Hodgkin’s
Lymphoma; this is not surprising given the higher diagnostc rate of this partcular cancer type in the 
adult populaton.  All partcipants were over the age of 18, and were either married or had a long-term 
partner.  83% of the sample were male.  All partcipants had been actvely treated with chemotherapy 
for their lymphoma, with one partcipant having first been monitored on ‘watch and wait’.  
Six partcipants were recruited in total.  Three focus groups were conducted, each containing two 
partcipants.  Though small, these group sizes were beneficial in order fully explore each partcipant’s 
experience, allowing for each individual narratve to emerge within a shared context, while stll allowing 
for a direct comparison between experiences within the group.  
Interview Schedule
The groups were designed to prompt discussion both with the interviewer, and between partcipants, 
about the type of needs experienced throughout each patent’s cancer experience, and to gain a level of
understanding of why some needs were highlighted as important while others deemed not relevant.  
The focus groups were facilitated to discuss the following key topics in the following schedule:
1. The majority of the session was spent discussing their met and unmet needs without 
promptng.
2. To spend some tme looking at the item pool drawn up from existng needs assessment tools 
(physical, psychological, identty, social, practcal, healthcare professionals, sexual, informaton,
communicaton, cognitve functon, financial, spiritual, employment) and to discuss the 
relevance of items.
3. The comparatve importance of both the needs that they themselves identfied and the needs 
identfied from the current assessment tools. 
4. Partcipants were then asked to highlight their key needs. 
Analysis of the data was open and not structured around existng needs, rather the research aimed to 
determine the extent to which themes generated did correspond with existng needs; and a level of 
refexivity was used both throughout the focus groups themselves and during the analysis process 
whereby the researcher was aware of the potental for bias and contnued to queston whether an 
existng knowledge of unmet needs in cancer was infuencing the current situaton.  
Results
Analysis of the data resulted in six super-ordinate themes as presented in Table 1.  Partcipants were 
assigned pseudonyms, which will be referred to throughout the results secton in order to preserve 
anonymity.  
Table 1: Super-and sub-ordinate themes.  
Super-Ordinate Themes Sub-Ordinate Themes
The Everyday Impact of Cancer Practcal
Physical
Psychological Needs Adjustment Throughout the Cancer Experience
The Importance of Environment
Perceptons of Self
Specific Areas of Psychological Need
The Need to Feel Supported 
Throughout the Cancer Experience
Social Support
Feeling Supported by Medical Professionals
Availability and Acceptability of Psychological Support
Being Supported as a Haematology Patent
Barriers to Accessing Support Feeling Unable to Ask for Help
Physical vs. Psychological
Psychosocial Concerns Not Discussed
Making Sense of the Cancer 
Experience
Personal Changes
Understanding My Experiences
Control
Need for Informaton Delivery of Informaton
Having Personalised Informaton Available
The Everyday Impact of Cancer
Being diagnosed with cancer was felt to impact upon daily routnes and on partcipants’ ability to 
contnue in their daily lives as they had done prior to their diagnosis.  This was felt to happen in two 
distnct ways: by afectng what people can and need to do practcally; and how physically able 
partcipants felt themselves to be.
Practcally, what had previously been viewed as simply part of everyday life, now became maters of 
concern that required atenton.
“I was thinking only the other day that I need to update my will” David
However, while present, practcal needs were felt to have been well supported by the healthcare teams 
at the hospital.
“They do go to quite a lot of efort don’t they to find out who you live with, who’s there. What your
property’s like” Mark
As a result of needs being met, there was litle in the way of associated psychological distress or anxiety.
This was also refected in how partcipants perceived the presence of physical need.  There was an 
expectaton that cancer would afect physical wellbeing, as such, these needs were expected by 
partcipants and healthcare professionals who were felt to be geared up to help with this.
“Anything around, if you needed, you know… the washing, the dressing, the sleeping stuf, yeah that
was dealt with” Mark
It was accepted that cancer treatment would have a physical impact.  The physical impact of treatment 
was perceived to vary across the sample but generally this was a tme when partcipants felt supported 
due to frequent contact with HCPs.  Once treatment ended, however, the level of support available to 
partcipants was felt to drop away without allowing partcipants tme to acclimatse which was felt by 
partcipants to be difcult to manage.  When combined with the on-going physical efects of cancer 
treatment, it was at this stage that the physical impact was harder to cope with as this defied the hope 
that life would return to normal afer treatment.
“It made me so ill.  It’s taken me… this is my hair now, and I lost it two years last August.  And this is all
I’ve stll got so you can imagine (…) but the fact that I’ve never been as thin as this in my life, and so you
feel a mess, a mess in clothes.  And so I found it hard to, to… get going to put one foot in front of the
other, I was just so exhausted.  And, I have to say, stll am a lot of the tme.” Daphne
Psychological Needs
Adjustng psychologically to the knowledge that they had cancer was felt to be far more difcult than 
the physical impact of disease.  The inital delivery of the diagnosis was felt to be important and had a 
real impact on how partcipants perceived their situaton, where conversatons around diagnosis were 
felt to be less sensitve than would be desired.
“Basically I sat in front of him and he said, “you’ve got cancer”… what you got is probably incurable, and
you need to see a specialist.  And then, of you go.  So.” David
Diagnosis was felt to be a crucial tme psychologically: one that had the potental to cause a great deal of
anxiety and distress.  Once this had been overcome, the end of treatment was also identfied as another 
pivotal tme in how people coped and adjusted to having cancer.  This later tme point is especially 
pertnent due to the swif and ofen unexpected removal of the safety net of regularly seeing clinicians, 
frequently being in the cancer treatment setng, and knowing that any concerns could easily be 
addressed.  Being lef to cope alone was difcult.  Partcipants described giving their all to ‘fightng’ their 
illness, and then being lef empty once the immediate danger had passed. 
“I just, having got the all clear and having got that leter, I just… just descended.  I just couldn’t face
anything.  And I don’t know… I’d just given everything.” Ray
It was at this point that partcipants’ sense of purpose could become lost, and uncertainty around what 
the future might hold sets in.
The perceptons of others were also felt to be important.  There was a need to believe that they would 
get beter and to keep positve, both from themselves and from those around them.  Where this was not
the case, the lack of positvity was difcult.
“a lot of people think as soon as you’ve mentoned cancer, they think god, we’ll be burying him soon.”
James
The importance of the perceptons of others was a theme that contnued throughout the focus groups.  
Partcipants felt that the way in which they were seen by others changed as a result of their cancer 
diagnosis and ofen meant that people felt labelled as a cancer patent rather than seen as an individual.
“I think, sometmes, when people are ill, some people see the illness and not the individual (…)I think
sometmes, if you’ve had cancer, people see you as a cancer suferer, or a recovering cancer suferer,
rather than as John or Fred.” David
Being treated as an ill person was difcult enough for these partcipants, but being seen as a ‘cancer 
patent’ was something even worse as this signified a greater deviaton from one’s own sense of self and
individuality.  
“I didn’t want to be defined…  I was prety touchy about it (…)it’s a small part of my life but it’s, you
know, I’m very happy that I’m being checked out every year but… did I want people to know at the
tme?” Mark
This feeling of changes to one’s very self was mirrored in changes to the body and body image.  Physical 
changes were felt to be a manifestaton of the disease that signalled to the world that they were ill.
“it was just a way of saying really, look there’s, there’s this problem.” Mark
Feeding from this, there was guilt associated with the percepton that body image could impact so 
greatly on psychological wellbeing, when one’s very life was under threat. And yet image was felt to be 
central to partcipants’ sense of self.  While the impact of cancer on body image was not felt to be of 
importance by friends and family, it matered to the person who was trying to maintain a sense of self 
throughout their experience.  
“But it’s the support network that…come on it doesn’t mater.  It does mater.  It maters what you… it
maters to the person.” Daphne
Other more specific areas of psychological need raised were fear of recurrence, maintaining hope, 
coping and struggling with emotons such as guilt and anger.  
The Need to Feel Supported Throughout the Cancer Experience
Feeling supported was important to all partcipants, and where it was absent, the consequent unmet 
need was felt keenly.  Both informal social support and support from healthcare professionals was 
important.  For all partcipants, support from haematology staf, including both the haematologist and 
haematology nurses, was felt to be of greater relevance than support from primary care clinicians.  
Relatonships with family and friends were valued highly, therefore, when support was not forthcoming, 
the resultng impact was strong.
“I was a litle bit surprised about who kind of put what into the pot.” Mark
However, partcipants identfied too that maintaining relatonships was difcult when there was so 
much else going on both practcally and emotonally.
“I didn’t want to make contact cos I just couldn’t cope cos I was up to here.” Daphne
Communicaton between the patent and professional was a key determinant of how well supported 
partcipants felt throughout their cancer experience.  Successful communicaton was defined by these 
partcipants as the giving of clear and individually-tailored informaton, and the way in which 
informaton was delivered was crucial.
“even though they kept explaining things… they use big words and names of stuf.” James
Regular contact from clinical staf during the diagnosis and treatment phases was welcomed and created
a feeling of being supported.  When treatment was completed, however, this sense of support was 
suddenly absent creatng feelings of isolaton and uncertainty.
“And then you’re fired of the end.  You’re at home aren’t you? Well, you are, and I think that maybe
that’s the tme when…” Mark
Given the noted importance of psychological needs, the need to feel that there was support available to 
address these needs was key.  There were diferences between partcipants in the extent to which 
formal support would have been desired,
“I’d rather have somebody prescribe something than deep, psycho, self analysis. It’s just not something
that I felt, I had a really strong support via my own wife and colleagues and friends” Mark
For those who were more open to receiving support, there was uncertainty around what help was 
available or how acceptable it was to ask for such help.
“you don’t get any interacton with a psychologist or someone who understands these things, if you are
feeling depressed, you would probably tend to keep it to yourself because you’re sat in a room with 12
other people.” David
A complicatng factor to feeling supported was the percepton that haematological cancers are diferent 
from other cancers.  There was a feeling that lymphoma is less well recognised and understood that 
other cancer diagnoses.
“they think cancer’s cancer, and it isn’t is it?” Mark
Haematological cancers were perceived not to fit well with other cancer diagnoses, instead feeling more
like living with a chronic illness.
“I’m in remission, and, you know, hope to be so for as long as possible but, there’s no outward signs.
Now, if you’ve had aggressive breast cancer and, for instance, you’ve had a mastectomy… and your
body image changes.  Whereas here there isn’t much to take away, it’s all, it’s more medicine than
surgery and it’s more like diabetes that’s controlled.” David
This created a sense of isolaton and separaton both from family and friends who were perceived not to
understand what these partcipants were experiencing, but also from other cancer patents who were 
perceived to have access to beter support services.  
“Now if you’ve got cancer, the Macmillan nurses are superb.” Daphne
This sense of separaton was compounded by a lack of outward signs of the disease.  This was felt to be 
both positve and negatve, in that it made it easier to get on with everyday life, but at the same tme 
heightened feelings of diference from both family and peers.  
“If you’ve got, breast cancer, or you have testcular cancer, or prostate cancer or kidney cancer or bowel
cancer, or something, you tend to lose, you tend to, you know, I’ve had colleagues and family members
who’ve had these other forms of specific cancers like that, and they do tend to look ill…  Whereas, I
didn’t.  I haven’t lost any weight.  I haven’t gained any but I haven’t lost any.  Um, I looked a bit grey the
day afer I’d had the chemo… and, what is both a good and a bad thing is that the people who, the
people that you meet and who know you’ve got this, forget it.”David
While many support services would categorise haematological diagnoses as cancer, partcipants crucially
did not and supportve care services were not seen as accessible or relevant to them.   Some partcipants
did access haematology-specific support groups that were run by natonal charites, but this involved 
travelling long distances to atend.  It was also highlighted how accessing peer support could be 
problematc, as it is difcult to remain positve about your won prognosis when others with the same 
diagnosis are seen to be becoming increasingly unwell or pass away.  
Barriers to Accessing Support
Psychological needs were repeatedly highlighted as important, yet ofen remained unmet through 
treatment as partcipants described feeling uncomfortable or unsure about raising their concerns with 
clinicians.  
“I think the support is there if you want it.  You just ask.  But I think sometmes, do you not think people
are afraid to ask? In case, because everyone’s busy, I think some people get it in their head, oh I can’t,
I’d beter not ask in case they’re busy.” Mark
Repeatedly, the busyness of the clinical environment was noted to be a barrier to expressing needs, with
clinicians already juggling many tasks, with some (i.e. treatment) taking priority.  As such, partcipants 
did not feel comfortable raising a concern that was seen as an aside to their cancer or their treatment, 
for fear of wastng the healthcare professional’s tme.  
“I kept saying that I, I’m sorry, I don’t like troubling you.” William
Hospitals were deemed places where cancer was treated and medical concerns addressed, therefore 
the physical aspects took predominance over the supportve, and thus psychologically-related concerns 
were not raised.  Partcipants instead put on a ‘brave face’ and maintained the façade that all was well.
“Unless they’ve got tme to spend speaking to you, they cannot hear what’s happening inside you.  And
it’s the bits you can’t see.” Ray
Making Sense of the Cancer Experience
Partcipants described feeling a need to make sense of their experiences, and forming comparisons with 
others was found to be a useful way of doing this while also helping to decrease feelings of isolaton.  
Seeing others survive and thrive afer cancer was viewed as a powerful source of hope; seeing others 
struggle on the hospital ward was difcult, however provided some form of comparison to determine 
how well they were individually coping.
“looking at others, and the way that some people only get halfway through their first lot of the day and
be really struggling… And it’s the determinaton of the staf, I felt that they were going about things in
such a way that just added to my own determinaton…  that I was going to deal with this, they were
doing so much and dealing with it so well, that, even if I had a problem, there was no way I could let
them know.” Ray
While forming comparisons could be positve, it could also create feeling of guilt that others were 
perceived to be coping with worse treatments, symptoms and prognosis.  This had the efect of creatng 
a barrier to asking for help and support from healthcare professionals for these patents who didn’t 
want to take clinicians’ atenton away from those with greater need.
Taking control of one’s own experience was a powerful force in enabling partcipants to own their 
experience and to make sense of what was happening to them.  
“I did feel as if we knew exactly where we were and what the next step was, and broadly what the
significance of every part of the interventon was.” Mark
For others, surrendering control to their clinicians and deferring to the perceived experts seemed a 
helpful way of placing the locus of control outside of themselves.
“There’s nothing you can do about it, you’re in the hands of other people who will hopefully do the right
thing for you.” David
Need for Information
Two aspects of informaton giving were deemed important: first, the actual delivery; and second, 
ensuring that it was personalised to the individual.  These partcipants reported that in their experience 
the delivery of informaton was generally appropriate. However, the need for clearer, concise 
informaton was emphasised.
“words of one syllable… and plain, simple English.” James
Having informaton about diagnosis and treatment was highly valued, yet the need for the informaton 
given to be relevant and wanted by the individual was highlighted repeatedly.
“when you first start you get all these generic leafets on, you know, how do you get a wig. I don’t need
a wig. What’s going to happen if…, what’s the likely side efect?” Mark
A sensible balance between a realistc prognosis while allowing the maintenance of hope was what all 
partcipants hoped for.  
Discussion
This paper highlights areas of unmet psychological and supportve care needs that are of partcular 
relevance to haematology patents.  Broadly, the needs discussed by these partcipants can be divided 
into two groups: those that te in with what we already know about unmet need in cancer, and those 
that add something new.  With the excepton of the themes centred around the specific diferences 
innate to being a haematology patent and the barriers to accessing support, the themes drawn from 
these focus groups indicate a level of similarity in the type of unmet need found in patents with 
difering cancer diagnoses (Armes et al, 2009).  It may be that for some areas of need, for example 
physical impact, psychological concerns or practcal maters, that type of need is common across cancer 
regardless of the specific diagnosis (Harrison et al, 2009).  
There were recurrent indicatons that, as haematology patents, partcipants felt themselves to be 
diferent from ‘cancer patents’: there was the lack of outward signs and the absence of looking ‘ill’; the 
separaton in treatment and associated terminology, for example being treated by haematologists 
rather than oncologists; and, for some, the modality of treatment was felt to difer, with lymphoma 
being likened to a chronic health conditon, rather than an acute cancer.   These perceived diferences 
were a cause of frustraton.  Feelings of isolaton, of being misunderstood by others, and of being less 
able to access appropriate support services compared with other cancer patents negatvely impacted 
these partcipants’ cancer experiences.   Feelings of isolaton or loneliness as a result of a cancer 
diagnosis have been highlighted previously (Helgason et al, 2001; Refsgaard and Frederikson, 2013), yet 
this has commonly been in relaton to changing lifestyles or altered relatonships with significant others, 
not as a result of diagnostc categorisaton.  Across this sample no partcipant identfied themselves as a 
‘cancer patent’.   Partcipants perceived their diagnosis to be poorly understood by both the general 
public (from which their informal social support is drawn) and by some healthcare professionals, notably
non-cancer professionals such as general practtoners: this was believed to be not the case for other 
cancers.   But, perhaps more importantly, partcipants did not identfy themselves as being cancer 
patents and this was evident in two distnct ways.  First, a widely held belief was that they were 
primarily haematology (or specifically lymphoma) patents: the perceived diferences between 
haematological and other cancers afected their views of both how acceptable services such as generic 
cancer support within the hospital or external charity-led support programmes were, and whether they 
felt comfortable accessing those support services when they do not identfy as a ‘cancer’ patent.   
Second, some patents simply did not wish to be associated with a ‘disease label’ at all, and the 
suggeston that they should adopt the label of ‘cancer patent’ was felt to be unrefectve of who they 
believe themselves to be, and the self that they wish to portray to the world.  If existng support services
are designed with cancer patents in mind, a group to whom partcipants did not feel a sense of 
belonging, then the applicability of such services to those with a haematological diagnosis may be 
questoned.  These partcipants were clearly unsure about whether these existng cancer services were 
available, or even relevant, to haematology patents.  In the absence of formal support services, 
partcipants were accessing support through their own social support networks or, in two cases, via 
disease-specific support groups.  It is not clear however, whether these choices were made out of 
preference for this type of support, or as a results of the perceived lack of alternatves.  These findings 
are novel and have not been reported elsewhere in the psychosocial oncology literature.  What we were
unable to ascertain from this study, however, was whether this perceptual diference comes from the 
patents themselves, or whether healthcare and support staf working in both oncology and 
haematology setngs perceive this diference too.   
Patents reported feeling uncomfortable about raising psychosocial issues with their clinicians, a 
situaton that was compounded by a perceived reluctance from clinicians who also did not typically raise
discussion of these kinds of concerns in the oncology clinic; the implicaton of this bi-directonal 
reluctance is that psychosocial concerns ofen simply weren’t discussed with anyone.  It has been 
recognised that clinicians can find it difcult to raise psychological issues with cancer patents, yet NICE 
(2004) have proposed a model of stepped-care to illustrate how clinicians at all levels can contribute to 
the maintenance of psychological wellbeing in cancer patents.  Unmet needs assessments such as the 
Holistc Needs Assessment (HNA) and the distress thermometer (Natonal Comprehensive Cancer 
Network, 2013) have been developed as tools to help clinicians detect distress, yet there is a great deal 
of variability in their use with the Natonal Cancer Patent Survey in 2011/2012 finding that only 24% of 
cancer patents were ofered a needs assessment and subsequent care plan (Department of Health, 
2012). Training packages have been developed that aim to improve clinician efcacy at detectng and 
managing distress within a general healthcare setng (Merckaert et al, 2005; Fallowfield et al, 2002).  
While these kinds of training programmes do seem to improve clinician confidence in their abilites and 
short-term competence (Fallowfield et al, 2003), there is less convincing evidence as to whether there 
are also improvements in ability to accurately detect distress or whether ultmately patent experience is
improved (Moorey, 2013).  The idea that cancer professionals do not always accurately detect the 
presence of psychological morbidity is not new (e.g. Fallowfield et al, 2001) and further work is needed 
to extrapolate the current evidence base in order to improve clinician confidence in raising psychological
concerns with patents and to ultmately improve the patent experience.  
This work also highlights barriers that are preventng patents who would benefit from psychological 
support from atemptng to access this.  If healthcare professionals do not raise psychosocial concerns 
within the clinic, and patents do not feel able to do so themselves, these needs will inevitably be lef 
unaddressed.  The need for HCPs to raise concerns and to feel confident in their abilites to do so is key.  
Existng research highlights the fact that many HCPs feel a lack of confidence in their ability to manage 
psychological distress (Moorey, 2013), as such there has been an infux of training programmes that aim 
to improve confidence and efcacy.  Evaluatons of these programmes have found that they do improve 
confidence but it is unclear as to whether there are also improvements in clinician ability to accurately 
detect distress and whether patent experiences are ultmately improved.  
While this study provides a valuable insight into the lived experiences of psychosocial needs in 
haematological cancer patent, it also highlights the need for ongoing and systematc quanttatve 
assessment of unmet need in haematology, just as is recommended for other cancer groups (Watson et 
al, 2012).   From a research perspectve, there is a need for large cohort studies, ideally with multple 
types of haematological diagnoses, recruited to inform the sector about the unmet needs of diferent 
patent groups, and to supplement this work on ideographic patent experiences.  Recommendatons by 
the Natonal Cancer Survivorship Initatve (2010) include the use of cohort studies as a way of mapping 
areas of need within cancer survivorship and as a method to develop priorites for future studies.  There 
is also a need to beter understand the supportve care preferences of this patent group.  It became 
apparent within this sample that partcipants had not accessed support services that were designed for 
‘cancer patents’, despite their unmet needs not appearing to difer greatly.  Future research should 
seek to establish whether a change in how existng support services are marketed to patents would 
increase uptake, or whether haematological cancer patents would prefer to access support services 
that are targeted towards their specific patent group.
There are both benefits and limitatons of conductng a study with a small sample size.  The intenton of 
this study was to beter understand patent experiences of need during cancer and how unmet needs 
impacted upon overall wellbeing; however, this does mean that applicability to the wider patent 
populaton is problematc.  Indeed, given the qualitatve epistemology of this study, applicaton of the 
findings to a whole patent populaton was not the objectve of the work.  Rather, this study was 
designed to provide a depth and richness that could fit alongside subsequent quanttatve works from 
which wider generalisaton could be inferred.   The small sample was, in part refectve of challenges 
encountered when atemptng to recruit partcipants into the study.  While homogeneity within the 
sample was appropriate given the use of IPA, it does refect a wider problem within psychosocial 
oncology research in atemptng to recruit diverse samples that refect society within the UK today.  
However, the dominance of males within the sample was deemed positve as men are typically harder 
to engage in psychosocial oncology research than women.  Indeed, difculty recruitng cancer patents 
into psychosocial studies is a challenge beyond that presented within this paper and is a challenge for 
psychosocial research in the UK today.
In conclusion, this work demonstrates a clear perceived diference between haematological cancer 
patents and other cancer patent groups.  Though drawn from a small sample, this work is novel and has
direct implicatons for both how these patents identfy themselves, and in reducing the perceived 
acceptability of support services that are designed for general cancer patent populatons.  
Understanding which unmet needs are most prominent is the crucial first step in designing interventons
and clinical services to begin to meet those needs, and this work clearly demonstrates the potental 
psychological impacts of such needs remaining unmet.  
The Author(s) declare(s) that there is no confict of interest.
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